AlphAIalphai — Financial news for AI agents
Intellectia AIMAR 304 min read$OSUR

OSUR PE Ratio & Valuation, Is OSUR Overvalued

OraSure Technologies Inc (OSUR) is currently undervalued, with a fair price estimated between $3.45 and $5.32 compared to its current price of $3.00. While its current P/S ratio of 1.48 is considered undervalued relative to its five-year average, it is still 47.52% above the industry average, which the analysis suggests may be unsustainable given robust revenue growth of -28.53%. The article provides various valuation metrics and compares them to historical averages and industry benchmarks.

Original reporting
Intellectia AI
Published Mar 30, 2026, 1:03 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 30, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
OSUR PE Ratio & Valuation, Is OSUR Overvalued — source image
Source · Intellectia AI
Decision brief

The 30-second read

$OSURNeutralMed
01

Why it matters

Valuation suggests undervaluation, but persistent revenue decline could lead to further price drops, emphasizing the need for cautious trading.

02

Market read

The article provides a nuanced view of OSUR's valuation, relevant for traders focusing on biotech stocks with valuation concerns.

03

What to watch

Possible upcoming catalysts (e.g., product launches, partnerships) that could improve revenue outlook and justify valuation levels.

Timing: short to medium term (1-6 months)

Background

OSUR has experienced significant revenue decline of -28.53%, raising concerns about its growth sustainability.

Company-level read

Ticker impact

$OSURNeutralMedium confidence
Context

Primary focus of the article, relevant for valuation and trading decisions.

Expected impact

Potential modest upward correction if valuation gaps close, but downside risk exists if revenue decline persists.

Evidence & confidence

Valuation metrics suggest undervaluation, but negative revenue growth and high P/S ratio relative to industry imply caution. Market sentiment is neutral, indicating no strong immediate directional bias.

Market effects

Sector

Potential valuation re-rating within the life sciences and biotech sectors, especially for companies with similar revenue profiles.

Regional

Limited; OSUR's valuation concerns are specific and unlikely to influence broader regional markets.

Global

Low; company-specific valuation issues with limited immediate global market impact.

Counterpoint

What could challenge this read

The negative revenue trend may persist, leading to further valuation declines, making current undervaluation a potential trap.

Key entities

  • Company
    OraSure Technologies Inc

    A biotech company specializing in diagnostic and health testing products.

Read at source← All news

Related articles

AUG 13
$OSURMedAI 8/10

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.

fool.com6 min
AUG 5
$OSURMed

ORASURE TECHNOLOGIES INC (OSUR): Results of Operations and Financial Condition

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 osur-pressreleaseq22026.htm EX-99.1 Document EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nas

SEC EDGAR 8-K6 min
JUL 22
$OSURMedAI 8/10

OraSure receives Emergency Use Authorization for second generation Ebola test

OraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.

wfmz.com3 min
JUN 11
$OSURMedAI 8/10

OraSure secures FDA clearance for product seen as key to future growth

OraSure (NASDAQ: OSUR) said the FDA has cleared its Colli-Pee at-home urine collection kit, made by subsidiary DNA Genotek, for use with Roche molecular diagnostic systems to identify multiple STIs. OraSure called the clearance important for future growth and noted it also filed for a rapid molecular self-test for Chlamydia and gonorrhoeae. Shares were up over 2% to $4.14.

wfmz.com4 min
JUN 11
$OSURMedAI 8/10

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies said the FDA cleared its Colli-Pee™•Dx urine collection kit (from subsidiary DNA Genotek) for at-home first-void urine collection for Roche cobas 5800/6800/8800 molecular testing. The kit supports tests for Chlamydia, Gonorrhea, Trichomonas vaginalis, and Mycoplasma genitalium, enabling mail-in workflows and decentralized STI screening.

manilatimes.net3 min
AUG 26
$AVEXLowAI 8/10

AVEX Shareholder Alert: October 20, 2026 Lead Plaintiff Deadline in AEVEX Corp. Securities Class Action - Contact Levi & Korsinsky

AEVEX Corp. (NYSE: AVEX) faces a securities class action lawsuit alleging its Board Chairman Brian Raduenz and others concealed a pre-arranged plan to waive a 180-day lock-up period for shareholders. The lawsuit claims misstatements in IPO documents led to a $900 million market value loss for AVEX shareholders in June 2026. The lead plaintiff deadline is October 20, 2026, according to Levi & Korsinsky, LLP.

prnewswire.com2 min